MREO
Price
$1.75
Change
-$0.01 (-0.57%)
Updated
Aug 28 closing price
Capitalization
279.84M
81 days until earnings call
RARE
Price
$30.30
Change
+$0.22 (+0.73%)
Updated
Aug 28 closing price
Capitalization
2.92B
67 days until earnings call
Interact to see
Advertisement

MREO vs RARE

Header iconMREO vs RARE Comparison
Open Charts MREO vs RAREBanner chart's image
Mereo BioPharma Group
Price$1.75
Change-$0.01 (-0.57%)
Volume$545.91K
Capitalization279.84M
Ultragenyx Pharmaceutical
Price$30.30
Change+$0.22 (+0.73%)
Volume$1.03M
Capitalization2.92B
MREO vs RARE Comparison Chart in %
Loading...
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MREO vs. RARE commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MREO is a Buy and RARE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (MREO: $1.75 vs. RARE: $30.30)
Brand notoriety: MREO and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MREO: 21% vs. RARE: 47%
Market capitalization -- MREO: $279.84M vs. RARE: $2.92B
MREO [@Biotechnology] is valued at $279.84M. RARE’s [@Biotechnology] market capitalization is $2.92B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MREO’s FA Score shows that 0 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • MREO’s FA Score: 0 green, 5 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, RARE is a better buy in the long-term than MREO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MREO’s TA Score shows that 4 TA indicator(s) are bullish while RARE’s TA Score has 4 bullish TA indicator(s).

  • MREO’s TA Score: 4 bullish, 3 bearish.
  • RARE’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, both MREO and RARE are a good buy in the short-term.

Price Growth

MREO (@Biotechnology) experienced а +6.06% price change this week, while RARE (@Biotechnology) price change was +2.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.11%. For the same industry, the average monthly price growth was +20.33%, and the average quarterly price growth was +29.99%.

Reported Earning Dates

MREO is expected to report earnings on Nov 18, 2025.

RARE is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Biotechnology (+2.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($2.92B) has a higher market cap than MREO($280M). RARE YTD gains are higher at: -27.977 vs. MREO (-50.000). MREO has higher annual earnings (EBITDA): -47.49M vs. RARE (-435.33M). RARE has more cash in the bank: 477M vs. MREO (56.1M). MREO has less debt than RARE: MREO (601K) vs RARE (36.3M). RARE has higher revenues than MREO: RARE (610M) vs MREO (500K).
MREORAREMREO / RARE
Capitalization280M2.92B10%
EBITDA-47.49M-435.33M11%
Gain YTD-50.000-27.977179%
P/E RatioN/AN/A-
Revenue500K610M0%
Total Cash56.1M477M12%
Total Debt601K36.3M2%
FUNDAMENTALS RATINGS
MREO vs RARE: Fundamental Ratings
MREO
RARE
OUTLOOK RATING
1..100
1321
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
72
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
8664
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RARE's Valuation (72) in the Biotechnology industry is in the same range as MREO (75) in the null industry. This means that RARE’s stock grew similarly to MREO’s over the last 12 months.

RARE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MREO (100) in the null industry. This means that RARE’s stock grew similarly to MREO’s over the last 12 months.

RARE's SMR Rating (100) in the Biotechnology industry is in the same range as MREO (100) in the null industry. This means that RARE’s stock grew similarly to MREO’s over the last 12 months.

RARE's Price Growth Rating (64) in the Biotechnology industry is in the same range as MREO (86) in the null industry. This means that RARE’s stock grew similarly to MREO’s over the last 12 months.

RARE's P/E Growth Rating (100) in the Biotechnology industry is in the same range as MREO (100) in the null industry. This means that RARE’s stock grew similarly to MREO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MREORARE
RSI
ODDS (%)
Bullish Trend 1 day ago
86%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
75%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
72%
MACD
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
77%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
76%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
74%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 1 day ago
78%
Declines
ODDS (%)
Bearish Trend 9 days ago
87%
Bearish Trend 18 days ago
80%
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
85%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CGVGX27.060.11
+0.41%
American Funds Global Insight 529-F-2
LGIEX21.36N/A
N/A
Franklin International Equity I
NGDLX32.67N/A
N/A
Neuberger Berman Large Cap Growth Inst
STMDX36.11N/A
N/A
Sterling Capital Real Estate I
IVOYX20.00N/A
N/A
Macquarie Mid Cap Income Opps Y

MREO and

Correlation & Price change

A.I.dvisor indicates that over the last year, MREO has been closely correlated with RARE. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if MREO jumps, then RARE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MREO
1D Price
Change %
MREO100%
-0.57%
RARE - MREO
69%
Closely correlated
+0.73%
TRDA - MREO
43%
Loosely correlated
-0.53%
CRNX - MREO
39%
Loosely correlated
+0.82%
NRIX - MREO
38%
Loosely correlated
-1.47%
RGNX - MREO
34%
Loosely correlated
+2.15%
More